Inquiry Basket
Loading ......
Filter By Product Search for
BARD1
BARD1 Full Name
BRCA1 associated RING domain 1
BARD1 Introduction
BARD1 (BRCA1 associated RING domain 1) is a DNA damage response protein and an important binding partner of BRCA1, making it highly relevant to researchers studying hereditary cancer, DNA repair defects, and therapeutic resistance. BARD1 forms a stable BRCA1–BARD1 heterodimer through its C-terminal domains, while its N-terminal RING domain contributes to ubiquitin ligase activity. This complex participates in the cellular response to DNA double-strand breaks and helps coordinate DNA repair, replication fork protection, and genome stability. For researchers evaluating BARD1 as a cancer target or biomarker, an important point is that BARD1 should not be interpreted simply as another BRCA1-related gene: its biological activity depends on protein domains, cellular context, and the specific isoform being expressed. Evidence from genetic and functional studies suggests that germline pathogenic BARD1 variants may contribute to hereditary breast cancer susceptibility, generally at a low-to-moderate penetrance level, although the strength of this association can vary among studies.
At the molecular level, BARD1 is best understood as a regulator of DNA damage repair rather than a single-function tumor suppressor. Through its interaction with BRCA1, BARD1 contributes to homologous recombination-associated repair and regulates the processing of DNA ends following double-strand breaks. Recent mechanistic work has further shown that BRCA1–BARD1 can stimulate long-range DNA end resection involving nucleases such as EXO1 and DNA2, while its activity can shift toward protecting damaged or stalled replication forks when RAD51 is present. This functional flexibility helps explain why experimental observations of BARD1 can differ according to DNA damage type, protein partners, and cellular conditions. BARD1 also has BRCA1-independent functions, including effects on apoptosis and transcriptional regulation. Importantly, alternative BARD1 isoforms generated through aberrant splicing or truncating alterations may have biological properties distinct from full-length BARD1, creating a major challenge when interpreting expression data, mutation studies, or potential therapeutic responses.
BARD1 has therefore attracted attention across breast, ovarian, pancreatic, lung, cervical, and other cancers, but its disease relevance is strongly context dependent. In hereditary cancer research, damaging BARD1 variants are particularly investigated as potential contributors to breast cancer risk, while in tumor biology, altered BARD1 expression or isoform patterns may be associated with tumor progression, prognosis, DNA repair capacity, and treatment response. Studies in pancreatic ductal adenocarcinoma and other malignancies suggest that BARD1 can display seemingly opposing tumor-suppressive or tumor-promoting effects depending on the isoform and molecular environment. This complexity is especially important for drug discovery: targeting total BARD1 expression may not produce the same biological outcome as selectively modulating a pathogenic isoform or exploiting a tumor's dependence on BARD1-associated DNA damage response pathways. Consequently, BARD1 remains a promising but biologically complex target for cancer genetics, biomarker development, DNA damage response research, and precision oncology, with future therapeutic strategies likely to benefit from distinguishing BARD1 isoforms, functional status, and the broader DNA repair context rather than treating BARD1 as a uniform cancer driver.
Alternate Names for BARD1
BARD1; BRCA1 associated RING domain 1; BRCA1-associated RING domain protein 1; BRCA1-associated RING domain gene 1;
Loading ......
